Risk of malignancy index (RMI) for prediction of malignancy in women with adnexal masses

Sukanya L (1)
(1) Department of Obstetrics and Gynaecology, Saveetha Medical College & Hospital, Chennai-602105, Tamil Nadu, India, India


Ovarian cancer is predominantly cancer in the perimenopausal and post- menopausal age group. A definitive biomarker has not been identified for malignant ovarian cancer and histopathology remains the diagnostic gold standard for this. Risk of Malignancy Index (RMI) in predicting malignant pelvic masses includes serum CA125 level, menopausal status, and ultrasonographic findings. The risk of malignancy index (RMI) was evaluated in the women presented with adnexal masses for its accuracy in predicting the malignancy. This was a retrospective study which included 120 women who presented with adnexal mass in a tertiary hospital. RMI scoring was done based on CA125 levels, ultrasound findings and postmenopausal status and RMI was correlated with the histopathological findings. Out of 120 subjects, 74.1% of subjects were proved to have malignant tumors. RMI in predicting malignancy showed a sensitivity of 88.76%, a specificity of 45.37%, a positive predictive value of 81.63%, a negative predictive value of 66.67% and an accuracy of RMI found to be 82.5%. The RMI is found to be a simple, cost-effective and reliable tool in predicting malignancy in women presenting with adnexal masses that helps in timely referral to a gynaecological oncology center for better management and survival. RMI scoring can be used as it is a better tool for analysing multiple parameters of the tumour.

Full text article

Generated from XML file


American Cancer Society. Global Cancer Facts & Figures 3rd Edition. Atlanta, 2018. American Cancer Society.

ICMR. Consolidated Report of Population Based Cancer Registries. In National Cancer Registry Program, Bangalore, 2006. Indian Council of Medical Research.

A Jemal, R Siegel, J Xu, and E Ward. Cancer Statistics. CA: A Cancer Journal for Clinicians, 60(5):277–300, 2010.

C S Herrington, E Robert Scully, Robert H Young, and Philip B Clement. Tumors of the Ovary, Maldeveloped Gonads, Fallopian Tube and Broad Ligament. In Atlas of Tumor Pathology, Third Series, Fascicle 23, volume 189 of 1, page 527, Washington, DC, 1998. Armed Forces Institute of Pathology. ISBN: 1 881041 43 3.

NCDIR. National Centre for Disease Informatics and Research, 2017. Indian Council of Medical Research. Annual Report 2016-2017.

I Jacobs, D Oram, J Fairbanks, J Turner, C Frost, and J G Grudzinskas. A risk of malignancy index incorporating CA 125, ultrasound and menopausal status for the accurate preoperative diagnosis of ovarian cancer. BJOG: An International Journal of Obstetrics and Gynaecology, 97(10):922–929, 1990.

P Geomini, R Kruitwagen, G L Bremer, J Cnossen, and B W J Mol. The Accuracy of Risk Scores in Predicting Ovarian Malignancy. Obstetrics & Gynecology, 113(2 (Part 1)):384–394, 2009.

T Ashrafgangooei and M Rezaeezadeh. Risk of Malignancy Index in Preoperative Evaluation of Pelvic Masses. Asian Pacific Journal of Cancer Prevention, 12(7):1727–1730, 2011.

Y Yamamoto, R Yamada, H Oguri, N Maeda, and T Fukaya. Comparison of four malignancy risk indices in the preoperative evaluation of patients with pelvic masses. European Journal of Obstetrics & Gynecology and Reproductive Biology, 144(2):163–167, 2009.

P A J Van Den Akker, A L Aalders, M P L M Snijders, K B Kluivers, R A K Samlal, J H A Vollebergh, and L F A G Massuger. Evaluation of the risk of malignancy index in daily clinical management of adnexal masses. Gynecologic Oncology, 116(3):384–388, 2010.

A Raza, T Mould, M Wilson, M Burnell, and L Bernhardt. Increasing the Effectiveness of Referral of Ovarian Masses From Cancer Unit to Cancer Center by Using a Higher Referral Value of the Risk of Malignancy Index. International Journal of Gynecological Cancer, 20(4):552–554, 2010.

K Al Musalhi, M Al Kindi, F Al Aisary, F Ramadhan, T Al Rawahi, K Al Hatali, and W. A Mula Abed. Evaluation of HE4, CA-125, Risk of Ovarian Malignancy Algorithm (ROMA) and Risk of Malignancy Index (RMI) in the Preoperative Assessment of Patients with Adnexal Mass. Oman Medical Journal, 31(5):336–344, 2016.


Sukanya L
sukanyalakshmanan91@gmail.com (Primary Contact)
Sukanya L. (2022). Risk of malignancy index (RMI) for prediction of malignancy in women with adnexal masses. International Journal of Research in Pharmaceutical Sciences, 13(3), 339–342. https://doi.org/10.26452/ijrps.v13i3.2733

Article Details

No Related Submission Found